- Title:
PDMR Dealing / Grant of Share Options - Time:
07:00:05 - Date:
8 Jul 2020 - Category:
Director/PDMR dealings - ID:
3190S
8 July 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch™, announces that it has today granted 210,000 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to Non-Executive Chairman, Dr Peter Pack. The options were granted under the Company's 2016 Non-Employee Share Option Plan with an exercise price of £1 per share.
One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
Following this grant, Peter Pack holds a total of 250,000 options over Ordinary Shares and is interested in 15,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.
The notification below, which is made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
| a) |
Name |
Peter Pack |
| 2 |
Reason for the notification |
|
| a) |
Position/status |
Director/PDMR |
| b) |
Initial notification/ Amendment |
Initial notification |
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
| a) |
Name |
Oxford BioDynamics Plc |
| b) |
LEI |
2138005Y1TK258O5U928 |
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
| a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
| b) |
Nature of the transaction |
Grant of share options |
| c) |
Price(s) and volume(s) |
210,000 ordinary shares at an exercise price of 100 pence per share
|
| d) |
Aggregated information - Aggregated volume - Price
|
N/A
|
| e) |
Date of the transaction |
8 July 2020
|
| f) |
Place of the transaction |
Outside a trading venue |
For further details please contact:
| Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
|
+44 (0)1865 518910 |
| Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield
|
+44 (0)20 7408 4090 |
| FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins |
+44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
PDMR Dealing / Grant of Share Options07:00:058 Jul 2020Director/PDMR dealings3190S